With positive PhIII data, Merck sets up a blockbuster attempt to overthrow Pfizer's reigning Prevnar 13
Merck is nearing the end of a years-long effort to dethrone Pfizer’s megablockbuster pneumococcal conjugate vaccine, Prevnar 13.
Straying away from its cash cow Keytruda, the NJ-based biotech says it will apply to license its candidate V114, which beats Prevnar by two pneumococcus strains, by the end of this year. The experimental vaccine met its primary immunogenicity objectives in two Phase III studies, according to Merck $MRK.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.